Project Grant R21AI185642
- This Project Grant award of $147,400.00, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to investigate the mechanisms by which antigen non-related CD4+ T cells contribute to the pathogenesis of skin fibrosis in systemic sclerosis (scleroderma) and sclerodermoid graft-versus-host disease. The project, conducted by Yale University, will use mouse models to...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $504,442 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the University of Pittsburgh. The grant aims to characterize molecular endotypes in pediatric scleroderma by integrating cellular and spatial transcriptomic data with histopathological patterns. This research will enhance patient stratification and inform personalized treatment strategies to...
- This Project Grant award of $389,754 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to assess the therapeutic potential of a peptide derived from collagen XVIII for treating lung fibrosis associated with systemic sclerosis (scleroderma). The project aims to evaluate the anti-fibrotic effects of this peptide in a murine model of lung fibrosis, as well as identify the minimal effective dose, optimal...
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) provides $173,719.00 to Boston University Medical Campus to conduct research on using Spatial Frequency Domain Imaging (SFDI) as an objective method to quantify and monitor skin changes in patients with Systemic Sclerosis (SSc), a severe autoimmune connective tissue disease. The research aims to prospectively evaluate SFDI's...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $172,584 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to The Trustees of Columbia University in the City of New York. The five-year grant, with a performance period from September 1, 2025 to August 31, 2030, will support research to prioritize genes potentially causal to the development of systemic sclerosis (SSc) using multi-omics analyses. The...
- The University of Michigan was awarded a $637,567 Project Grant by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The project, which runs from September 19, 2025 to August 31, 2030, will investigate the role of the A20 and DREAM proteins in adipogenesis (fat cell development) and their potential contribution to the pathogenesis of systemic sclerosis (SSc), a debilitating...
- This Project Grant award was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The $113,090 award, made on May 15, 2025, supports research by Dr. Mengqi Huang at the University of Pittsburgh to investigate the epigenetic regulatory networks driving increased expression of TGF-β3 in systemic sclerosis skin myofibroblasts. The research aims to advance knowledge of...
- The federal Project Grant award of $498,436.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support a study to validate quantitative outcomes for measuring changes in systemic sclerosis (SSc)-associated calcinosis cutis, a debilitating skin condition. The study, conducted by Yale University, will evaluate the performance of the Mawdsley Calcinosis Questionnaire and...
- This Project Grant award, totaling $176,148.00 and effective from April 1, 2025 to March 31, 2030, was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The funding supports a research project led by Dr. Maxime Kinet at the University of California, San Francisco (UCSF) that aims to elucidate the mechanisms by which PI16-expressing fibroblasts, a...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $722,667.00 to the University of Texas Health Science Center at Houston to conduct research on ribosome dysfunction and its role in lung fibrosis associated with systemic sclerosis (SSc). The research aims to identify the mechanisms linking enhanced ribosome biogenesis to an altered translatome that drives lung fibrosis in SSc patients. The project will utilize...
T CELL-MEDIATED CONTROL OF DERMAL FIBROBLAST GENE PROGRAMS AND DYSFUNCTION IN SCLERODERMA - PROJECT SUMMARY/ABSTRACT SYSTEMIC SCLEROSIS (SSC), ALSO KNOWN AS SCLERODERMA, IS AN IDIOPATHIC DISEASE OF THE CONNECTIVE TISSUE CHARACTERIZED BY FIBROSIS OF THE SKIN AND UNDERLYING ORGANS. IT HAS THE HIGHEST MORTALITY OF ALL RHEUMATIC CONDITIONS AND NO CURE. T CELLS PREDOMINATE IN LESIONAL SSC SKIN AND PATIENT SERUM IS ENRICHED IN T CELL CYTOKINES. IMMUNOSUPPRESSION THAT LIMITS T CELL FUNCTION CAN DECREASE SYMPTOMS OF FIBROSIS, BUT ALSO INCREASES PATIENT SUSCEPTIBILITY TO INFECTION. AN ARRAY OF FUNCTIONALLY DISTINCT T CELLS ARE IN CLOSE-CONTACT WITH FIBROBLASTS IN HEALTHY SKIN, AND DYSREGULATED T CELL-FIBROBLAST CROSSTALK IS THOUGHT TO BE A MAJOR DRIVER OF DISEASE PATHOLOGY. HOWEVER, WHILE T CELLS ARE IMPLICATED IN SSC PROGRESSION, NO STUDIES HAVE PERFORMED A RIGOROUS MECHANISTIC DISSECTION OF T CELL-DIRECTED CHANGES TO FIBROBLAST GENE PROGRAMS IN HEALTHY AND FIBROTIC SKIN. WE PREVIOUSLY IDENTIFIED A NOVEL POPULATION OF CUTANEOUS CD4+CLA+CD103+ T CELLS IN THE BLOOD AND SKIN THAT CO-PRODUCE IL-22 AND IL-13 IMPLICATING A ROLE IN SKIN HOMEOSTASIS. WE NOW FIND THAT THE FREQUENCY OF THESE AND OTHER CUTANEOUS T CELLS ARE ALTERED IN SSC, THOUGH THEIR FUNCTION IN AFFECTED PATIENT SKIN REMAINS UNEXPLORED. OUR NOVEL PRELIMINARY DATA SHOW THAT DIFFERENT CUTANEOUS T CELL POPULATIONS PROMOTE DISTINCT FIBROBLAST GENE SIGNATURES AND DEMONSTRATE A STRONG CD103+ T CELL-DEPENDENT EFFECT ON A NEWLY IDENTIFIED SSC-ASSOCIATED FIBROBLAST SUBSET. WE THEREFORE HYPOTHESIZE THAT CD103+ T CELL ACTIVITY IS ESSENTIAL FOR FIBROBLAST HOMEOSTASIS AT THE STEADY STATE AND THAT NORMAL T CELL-FIBROBLAST INTERACTIONS ARE DISRUPTED IN SSC, LEADING TO FIBROBLAST DYSFUNCTION. THIS PROPOSAL WILL USE SINGLE- CELL SPATIAL TRANSCRIPTOMICS AND INNOVATIVE ORGANOTYPIC SKIN CULTURE TO FILL CRITICAL KNOWLEDGE GAPS AND OVERCOME EXISTING TECHNICAL HURDLES IN THE FIELD. COMPLETION OF THESE AIMS WILL BUILD A FOUNDATION FOR THE GENERATION OF EXCITING NEW HYPOTHESIS AND WILL ADVANCE A NOVEL ORGANOTYPIC CULTURE MODEL WITH THE POTENTIAL TO RECAPITULATE IN VIVO FIBROBLAST HETEROGENEITY ASSOCIATED WITH DISEASE AND TISSUE DYSFUNCTION.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $216.6k | 4/25/25 | ||
| Not listed | $26.0k | 9/11/24 | ||
| Not listed | $26.0k | 9/11/24 | ||
| Not listed | $234.0k | 6/12/24 | ||
| Not listed | $234.0k | 6/12/24 |